Abstract
Declining vaccine coverage across the United States has increased the risk of outbreaks of vaccine-preventable diseases. Even when vaccines have low primary failure rates, conventional epidemic theory predicts a strongly nonlinear, positive relationship between vaccine coverage and the fraction of breakthrough infections in vaccinated individuals. These breakthrough infections may generate misconceptions that vaccines are not working and accelerate declines in confidence and coverage. Here, we set out to test predictions of conventional epidemic theory that assumes random mixing between individuals irrespective of vaccine status. In contrast to expectations from random mixing models, we find a far lower fraction of breakthrough infections in measles outbreak data from seven states in the United States. To explore this discrepancy, we evaluate an alternative, compartmental disease model that accounts for preferential mixing (‘assortativity’) between people with the same vaccination status. The model predicts significantly lower fractions of breakthrough infections, consistent with observations from measlesoutbreak data. Next, we leverage the deviation between statewide and school-level vaccine MMR coverage across kindergartens in sixteen states, finding substantial assortativity in all cases. Our model accounting for preferential mixing predicts the total number of breakthrough infections is nonlinear, peaking at intermediate coverage below vaccine-derived herd immunity. Nationally, 94% of counties that report MMR coverage are above the model-predicted breakthrough-maximizing coverage, suggesting that they are at risk for increasing breakthrough infections if coverage declines. Vaccination outreach and monitoring campaigns should develop proactive strategies to contextualize breakthrough infections before low levels of primary failure contributes to population-scale increases in preventable disease.
Significance Statement Infections among vaccinated people may exacerbate vaccine hesitancy. Despite reports of ‘breakthrough infections’ within ongoing measles outbreaks, we show that the realized fraction of breakthrough infections is far lower than predicted by conventional epidemic theory that assumes random mixing. Combining epidemic models and school-level vaccine coverage data, we show that breakthrough infections may be partially limited via preferential mixing (‘assortativity’) based on vaccination status. Given current MMR coverage, most of the country is at risk for increasing breakthrough infections if vaccine coverage declines further. We conclude that enhanced vaccine monitoring and outreach campaigns are needed to confront a potential positive feedback loop between increasing breakthrough infections and declining vaccine coverage that could substantially increase the burden of vaccine-preventable disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.J.H., S.J.B., and J.S.W. are investigators at the University of Maryland-Institute for Health Computing, which is supported by funding from Montgomery County, Maryland and The University of Maryland Strategic Partnership: MPowering the State, a formal collaboration between the University of Maryland, College Park and the University of Maryland, Baltimore. This work is supported by a Simons Foundation grant to J.S.W. (MPS-SIP-00930382). N.C.L. is supported by the National Institutes of Health (NIAID) New Innovator Award (DP2AI170485).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All associated code has been uploaded to Github at https://github.com/WeitzGroup/Breakthrough-Infections/ and is archived on Zenodo at https://doi.org/10.5281/zenodo.18332220. Publicly available outbreak and vaccination data across six states are included in the repository, while data obtained via correspondence with public health departments in ten states are withheld.
